Actelion’s Opsumit (macitentan) made it easier for blood to pass through the lung blood vessels of chronic thromboembolic pulmonary hypertension (CTEPH) patients, a Phase 2 clinical trial suggests. In addition to lowering patients’ lung blood pressure, Opsumit also improved their ability to exercise, and was safe, researchers said. The trail…
Search results for:
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension caused by chronic blood clots in the lungs. It can lead to right heart failure. While treatable with surgery, the drug Opsumit is a viable option for inoperable patients.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
New research is shedding light on the progression of CTEPH. A novel study on chronic thromboembolic pulmonary hypertension (CTEPH), entitled “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients” published in the European Respiratory Journal by Dr. Diana Zabini, part…
The Pulmonary Hypertension Association (PHA) is planning a series of events for November, Pulmonary Hypertension Awareness Month, including a daylong focus on chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that results from blood clots in the lungs. Events planned for CTEPH Awareness Day, Nov. 15, include promoting information about the two…
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension (PH), a disease associated with abnormally high pressure in the blood vessels of the lungs, caused by the formation of blood clots. CTEPH also can be referred to as group 4 PH, the World Health Organization classification that…
Social Clips
Thromboembolic Pulmonary Hypertension
“In this video, from the Texas Heart Institute, meet Deborah Meyers, MD, and her patient Trasetta Terry, a retired pharmacist who tells us about her experience with thromboembolic pulmonary hypertension.” Keep up to date on all the latest PH news here: https://bit.ly/20LXxHN…
https://vimeo.com/184579437 In this video from Elsevier Pharma Solutions, Professor Marc Humbert discusses the diagnostic processes for pulmonary hypertension and chronic thromboembolic pulmonary hypertension (CTEPH)—which is a curable form of the disease. RELATED: A study find international diagnosis and management of CTEPH is inadequate. Prof. Hubert explains that CTEPH is…
People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) has been identified as one of the major causes of acute pulmonary hypertension (PH). This condition is characterized by a progressively dangerous accumulation of blood clots within pulmonary vasculature, which leads to PH and can eventually cause right-sided heart failure. It…
In this video from PHA Canada, meet Dr. Sanjay Mehta. Dr. Mehta is a CTEPH-treating doctor and in this clip shared in 2014, he discusses some important information on CTEPH and pulmonary hypertension. Read the latest updates on pulmonary hypertension: https://bit.ly/1K4oewk…
Recently published data from the CHEST-2 clinical trial showed that riociguat (Adempas) is both safe and effective as a longer term treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The study also identified two predictive biomarkers distinguishing CTEPH and pulmonary arterial hypertension (PAH), and their concentrations serve as prognostic guides of…
Metabolic differences affecting energy production were observed in endothelial cells — the cells that line blood vessels — from patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). These distinctions could underlie differences in disease mechanisms and necessary treatment approaches, according to a recent study.
Balloon pulmonary angioplasty, a procedure to widen narrowed lung blood vessels, was still benefitting patients with chronic thromboembolic pulmonary hypertension (CTEPH) six months after doctors performed it, a Japanese study found. The procedure increased patients’ cardiac output, or amount of the blood the heart is pumping, and exercise capacity, researchers said.